Shares Investor Evening (London) - 06 June 2018

Finding investment ideas for your portfolio. If you are a new investor just starting to invest on your own or a well-experienced one, many investors are interested in selecting individual stocks for their own portfolios, but arent sure where to begin their search for a great investment idea.

Come along to the Shares and AJ Bell Investor Evening in London on 6 June 2018 and listen to and meet Directors of listed companies who you can invest in.

Amryt Pharma (AMYT) - is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

Diurnal (DNL) - Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions. They are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). Diurnals expertise and innovative research activities focus on circadian-based endocrinology (mimicking the bodys natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.

Midatech Pharma (MTPH) - Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatechs strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.